An Introduction to COPD
Multitargeted approaches to symptom relief and novel disease-targeting interventions are improving the clinical management of chronic obstructive pulmonary disorder (COPD). Recently approved fixed-triple therapy in a single inhaler reduces treatment burden, improves therapy compliance and symptom relief. Inhibiting pro-inflammatory eosinophils, valve surgery and airway tissue regeneration are currently being explored. Patient-focussed pulmonary rehabilitation strategies are offering a more holistic approach to care, improving well-being and quality of life for patients living with COPD.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Blood Eosinophils in Chronic Obstructive Pulmonary Disease: Is There Enough Evidence?
touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):31–7
The lack of well-validated biomarkers for monitoring disease activity, predicting future clinical outcomes and the effect of therapeutic interventions highlights the need to find new biomarkers in chronic obstructive pulmonary disease (COPD). In recent years, extensive research has gone into identifying and attempting to validate relevant diagnostic biomarkers of disease activity and therapeutic response.1 A […]
Updates in the Management of Alpha-1 Antitrypsin Deficiency Lung Disease
touchREVIEWS in Respiratory & Pulmonary Diseases. 2021;6(1):26–30
Alpha-1 antitrypsin (AAT) deficiency (AATD) is the second most common genetic disease to cause clinically significant lung disease, surpassed only by cystic fibrosis.1 AAT is a serine protease inhibitor primarily produced in hepatocytes, with a normal plasma level of 20–53 µM or 90–200 mg/dL and a half-life of 3–5 days.2 AAT is transported via the systemic circulation […]
Donald Mahler, CHEST 2021: Precision Medicine in COPD
We were delighted to speak with Prof. Donald Mahler (Geisel School of Medicine, Dartmouth, NH, USA) to explore his presentation ‘Precision Medicine in COPD’, which was presented at CHEST 2021, 17-20 October 2021. Questions What is the limitation of traditional approaches to the treatment of COPD? (0:26) What are the major challenges of moving to […]
Douglas Mapel, ATS 2021: The Rate of ED Visits in Patients with COPD in the IMPACT Trial
It was a pleasure to meet with Dr Douglas Mapel (Northern Arizona Pulmonary Associates – Critical Care, Flagstaff, AZ, US) to talk around his abstract on ‘Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial.‘, which was presented at ATS 2021 International Conference, 14-19 May, […]
Highlights From The 2020 European Respiratory Society Industry Symposium “Mind The Gap: Evidence On The Treatment Of Alpha1-Antitrypsin Deficiency And Unmet Needs”
This content is for Healthcare Professionals based in the following countries only: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, Germany, Greece, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Saudi Arabia, Spain, Sweden, Switzerland and Turkey.
Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma
US Respiratory & Pulmonary Diseases. 2020;5(1):18-23 DOI: https://doi.org/10.17925/USPRD.2020.5.1.18
Strategy reports from both the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20201 and the Global Initiative for Asthma (GINA) 20192 highlight the importance of using the triple combination of inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs), and long-acting muscarinic receptor antagonists (LAMAs) in the treatment of chronic obstructive pulmonary disease (COPD) and asthma, respectively. However, there is […]
Brian Carlin, CHEST 2020 – New Thoughts in COPD
Brian Carlin (Pittsburgh Critical Care Associates, Pittsburgh, PA, US) talks to us about recent developments in the treatment of COPD and the impact COVID-19 has had on pulmonary rehabilitation services. Questions 1. What have been the most exciting recent developments in inhaled therapies for COPD? (0:20) 2. What factors should physicians consider before prescribing inhaled […]
Peter J Barnes, ERS 2020 – Smart Inhalers for COPD and Asthma
During the ERS International Congress 2020, it was great to catch up with our Editorial Board member, Prof. Peter J Barnes (Imperial College, London, UK), to continue the discussion around Smart Inhalers and how they could help optimise inhaler use in patients. Questions How common is poor adherence and inhaler technique in people with asthma […]
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 1)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. What are the limitations of current pulmonary rehabilitation programmes? (0:05) 2. What are the potential advantages and limitations of tele-rehabilitation? (1:44) Speaker disclosures: Henrik Hansen […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!